California is strengthening oversight of its legal marijuana market with a new law requiring retailers to provide cannabis laboratory reports to customers who request them, while giving state regulators clearer tools to check products on store shelves and evaluate the laboratories responsible for testing them. Governor Gavin Newsom announced his signature of Assembly Bill 1965 on September 27, 2026, advancing a consumer-protection measure focused on the reliability of the information behind a cannabis product’s label.
Authored by Assemblymember LaShae Sharp-Collins, a San Diego Democrat, the legislation addresses a fundamental question for California’s regulated industry: how can consumers trust that a product’s potency and safety claims reflect what is actually inside the package? The law combines access to certificates of analysis with stronger accountability for testing practices. Its significance extends beyond making laboratory paperwork available. It creates additional opportunities to compare a product’s official test results with independent checks and to identify problems that a passing certificate alone might conceal.
What California’s New Cannabis Testing Law Changes
AB 1965 amends the state’s cannabis regulatory framework in several connected areas. Licensed sellers must provide the certificate of analysis associated with cannabis goods held or offered for retail sale when a customer requests it. Retail licensees must also allow the Department of Cannabis Control, or DCC, to obtain or access products for off-the-shelf testing. Laboratories must comply with department requests to evaluate their testing practices, and the legislation expressly addresses performance testing intended to assess consistency across laboratories. Together, these provisions strengthen scrutiny of both the products being sold and the businesses certifying them.
The measure passed the Assembly 73–0 in May and the Senate 39–0 in August before reaching Newsom’s desk. Although the governor has now signed it, enactment should not be confused with immediate implementation. The enrolled measure contains no urgency clause or alternative effective date, placing it on California’s ordinary January 1, 2027, timetable for regular-session legislation. Businesses therefore have a preparation period, while consumers should distinguish the coming statutory requirement from retailers’ existing voluntary practice of sharing reports. How effectively the changes work will depend partly on the procedures used to implement them.
Consumers Will Be Able to Request the Report Behind the Label
A certificate of analysis, commonly called a COA, records laboratory findings for a particular cannabis batch. It supplies information that a package’s THC number or a general claim of laboratory testing cannot communicate by itself. California’s DCC explains that these reports identify whether a batch passes or fails testing for the substances examined. The state’s testing framework covers cannabinoid content and categories including pesticides, residual solvents, heavy metals, microbial impurities and mycotoxins. Making the underlying report available gives shoppers a way to examine the evidence supporting a product’s sale.
The practical value is greater visibility at the point of purchase. A consumer comparing products could ask to see the relevant certificate and check whether its identifying information corresponds to the item being offered. A retailer’s ability to retrieve the right report also matters: a certificate for another batch of the same brand cannot establish the tested condition of the package in front of the customer. AB 1965 establishes access upon request; it does not itself create a universal public website containing every laboratory result or require a QR code on every package. Those are different mechanisms for delivering information.
Off-the-Shelf Testing Adds a Check After Products Reach Retail
California already requires cannabis goods to undergo compliance testing before sale. The new retail-access provision strengthens the state’s ability to examine what reaches customers after that initial checkpoint. Under AB 1965, a licensed seller must allow the DCC to obtain or access cannabis goods held or offered for retail sale for laboratory testing. This puts an explicit obligation on retailers to cooperate with that form of oversight, rather than treating the original certificate as the last relevant word about a product’s compliance.
Independent testing of retail inventory can help regulators investigate whether the product and its paperwork agree. A discrepancy would still require interpretation: the significance of a difference depends on what was measured, the methods used, sampling conditions and applicable standards. An unexpected result should lead to an investigation, not an automatic assumption that every difference proves fraud. Nevertheless, the ability to examine goods available to shoppers is a meaningful accountability tool. It creates a route for checking the system’s output where it matters most—at the stage when a product can enter a consumer’s hands.
Laboratories Face Greater Scrutiny of Their Performance
Product testing is only as useful as the reliability of the laboratory performing it. California already requires licensed cannabis laboratories to maintain ISO/IEC 17025 accreditation, use operating procedures, establish quality-assurance programs and participate in proficiency testing. AB 1965 adds explicit statutory language concerning DCC performance testing and cooperation with evaluations of laboratory practices. The text identifies blind proficiency testing and round-robin testing among the approaches available to assess competence and consistency, without prescribing a single universal testing schedule for every laboratory.
These approaches can examine reliability from different directions. Proficiency testing assesses whether a laboratory can produce acceptable results on a test sample; comparisons across laboratories can reveal whether measurements are consistent or whether a particular laboratory warrants closer examination. For consumers, that scrutiny matters because reading a report cannot establish that its underlying analysis was performed correctly. Transparency and technical oversight therefore serve complementary purposes. Access lets a customer inspect the reported findings, while laboratory evaluation helps determine whether those findings deserve confidence. Neither function can fully substitute for the other.
Retesting Becomes More Flexible, With an Important Trade-Off
One provision makes the law more nuanced than a straightforward tightening of every testing rule. Existing statutory language required both written notification to the DCC about a compromised test and department authorization before the relevant retest could proceed. AB 1965 changes that structure. It permits retesting under specified circumstances involving written notice of equipment malfunction, staff error or other circumstances allowed by regulation, as well as when the department requires or authorizes a retest. That adjustment can allow laboratories to address legitimate analytical problems more directly.
However, the Assembly’s policy analysis identified a potential weakness: reducing the need for prior approval could create opportunities for abuse if claims of equipment malfunction or staff error are not adequately controlled. That concern deserves attention alongside the law’s consumer benefits. Correcting a demonstrably compromised analysis is different from repeating a valid test because its result is commercially inconvenient. Effective oversight will need to preserve that distinction through records, defensible procedures and regulatory review. The retesting provision should not be interpreted as unrestricted permission to keep testing a batch until a preferred result appears.
Why Potency Inflation and Lab Shopping Matter
The reform arrives amid California’s broader effort to address testing practices that can distort the legal market. In a separate rulemaking explanation, the DCC describes “lab shopping” as obtaining results from multiple laboratories for a batch and selecting favorable findings, such as a higher THC number or a result below a contaminant limit. The department warns that these incentives can disadvantage laboratories that report accurate findings. The problem is therefore both a consumer-protection issue and a competitive issue: reliable testing becomes harder to sustain when unfavorable scientific results drive customers elsewhere.
The economic incentives are significant even when a product’s appearance does not change. An inflated potency result can make one batch seem more valuable than a comparable product with an accurate label, while an improperly obtained passing result can allow questionable inventory to move forward. State-commissioned analysis of testing data has examined unusual laboratory patterns, but it also cautions that a statistical irregularity does not necessarily prove inaccurate results or participation in lab shopping. Oversight must combine data analysis with investigation. Treating every unusual number as wrongdoing would be as unsound as accepting every certificate without scrutiny.
The Signed Law Is Separate From Pending Tracking Reforms
AB 1965 should not be confused with the DCC’s separate Track and Trace Updates proposal, identified as DCC-2026-02-R. That regulatory package targets opportunities to manipulate sampling and electronic records. Its proposed changes include limiting compliance sampling to one laboratory and one representative sample, subject to specified exceptions, and restricting actions that could disconnect a batch from its testing history. It also proposes consumer access to COAs. The department’s posted rulemaking materials identify a June 5, 2026, notice and a public-comment process that summer; those documents describe proposed regulations rather than a final effective rule.
The distinction matters because the two efforts address related problems through different legal routes. Newsom’s signature confirms enactment of AB 1965, but it does not automatically finalize every provision in the department’s tracking proposal. Readers should be cautious about accounts that combine laboratory performance testing, customer access, sampling restrictions and electronic transfer controls into one newly effective package. The signed legislation establishes specific statutory changes. The separate rulemaking process concerns additional operational safeguards, and its final requirements and timing must be assessed on their own record.
What a Cannabis Lab Report Can and Cannot Tell Shoppers
A useful way to approach a COA is to begin with identification rather than potency. The report should correspond to the product and batch being considered, and the laboratory findings should be read as a whole. A prominent cannabinoid percentage does not explain the results of contaminant testing. Where a report includes technical abbreviations or unfamiliar units, asking the retailer for clarification is more useful than assuming that every low number means the same thing. Reports are most informative when customers understand what was tested and how the findings relate to the item being sold.
A passing report also has limits. It describes the sampled material and the tests performed under the applicable standards; it is not proof that every conceivable contaminant was investigated or that cannabis use carries no risk. Nor does a COA establish whether a product is medically appropriate for an individual or predict exactly how that person will respond. Greater access should improve the quality of questions consumers can ask, without turning a technical document into a blanket assurance. The strongest benefit is a more specific, verifiable conversation about the product replacing a vague claim that it was tested.
Implementation Will Determine the Law’s Value
For retailers, preparation should center on being able to retrieve the correct certificate for current inventory and explain what it represents. For laboratories, the changes reinforce the importance of documented methods, defensible retesting decisions and cooperation with oversight. These are practical responsibilities with direct consequences for whether the law delivers meaningful transparency. A customer-access requirement will have limited value if employees cannot locate the relevant report, just as additional evaluation authority will have limited effect without consistent follow-through when testing practices raise concerns.
California has now placed more responsibility on its legal cannabis market to support product claims with accessible evidence and regulatory verification. Consumers stand to gain a clearer view of laboratory findings, and compliant businesses could benefit from closer scrutiny of unreliable competitors. Those outcomes remain goals to be demonstrated through implementation. The measure’s success will be judged by whether customers receive accurate batch-specific reports, regulators can effectively check retail products, and questionable laboratory practices are identified and corrected before they undermine confidence in the market again.
